Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FG-M701
- Development stage
- Phase 2
- Lead developer
- AbbVie
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
FG-M701 (also known as ABBV-701) is a fully human monoclonal antibody developed for the treatment of inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. It targets Tumor necrosis factor-like cytokine 1A (TL1A), a clinically validated target in IBD. The drug is engineered to potentially offer best-in-class efficacy and less frequent dosing compared to first-generation TL1A antibodies. Initially developed by FutureGen Biopharmaceutical, AbbVie has obtained exclusive global rights to develop, manufacture, and commercialize the therapy. As of April 2025, it is in Phase 1 clinical trials.
02
Targets
Beyond the preview
Go deeper on FG-M701.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FG-M701.